![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 44, 40385-40388, November 2, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
B Signaling Pathway Governs TRAIL Gene Expression and Human
T-cell Leukemia Virus-I Tax-induced T-cell Death*
From the Department of Microbiology and Immunology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033
Received for publication, August 31, 2001
| |
ABSTRACT |
|---|
|
|
|---|
The Tax oncoprotein encoded by human T-cell
leukemia virus induces both T-cell activation and apoptosis. The
mechanism by which Tax induces apoptosis has remained unclear. Using
genetically manipulated T-cell lines, we demonstrate that Tax-induced
T-cell death is dependent on NF- Human T-cell leukemia virus type I
(HTLV-I)1 is an oncogenic
retrovirus etiologically associated with the development of adult T-cell leukemia (1, 2). HTLV-I induces T-cell transformation both
in vivo and in cell culture, and this transformation appears to involve a multistep process (3). At least in vitro,
HTLV-infected T cells initially undergo proliferation and massive cell
death, or apoptosis, followed by the appearance of immortalized cell clones (4) that appear to be equipped with anti-apoptotic factors (5).
Over time, the immortalized T cells accumulate genetic abnormalities,
leading to the generation of monoclonal transformed T-cell clones (3,
4). Emerging evidence suggests that both the apoptosis and
immortalization of HTLV-infected T cells are mediated largely by the
viral oncoprotein Tax (6-9).
Tax-induced T-cell immortalization involves aberrant induction of
various growth-related cellular genes such as those encoding interleukin-2 (IL-2) and the The mechanism by which Tax induces T-cell death remains largely
unknown. A recent study suggests that this virus-specific event
requires caspases (23), cysteine proteases that serve as common
intracellular mediators of apoptosis (24). However, it is unclear
whether Tax-mediated apoptosis involves any of the tumor necrosis
factor (TNF) family of extracellular death regulators. This family
includes TNF- Cell Lines--
The parental Jurkat cell line and its
derivatives, JM4.5.2, JM4.5.2-GFP, and JM4.5.2-IKK Reagents and Antibodies--
Phorbol 12-myristate 13-acetate
(PMA) and ionomycin were purchased from Sigma and used at a
concentration of 10 ng/ml and 1 µM, respectively. The
anti-TRAIL-blocking antibody (RIK-2) was provided by Dr. H. Yagita
(28). The anti-Fas-blocking antibody (M3) was provided by Immunex Corp.
(29). The anti-Tax and anti-CD28 monoclonal antibodies were prepared
from hybridoma 168B17-46-34 (provided by the AIDS Research and
Reference Program, NIAID, National Institutes of Health) and 9.3 (provided by The Fred Hutchinson Cancer Research Center), respectively.
FITC-conjugated annexin V (annexin-FITC) and propidium iodide were
purchased from Roche Molecular Biochemicals.
Retroviral Transduction--
Retroviral transduction was
performed using the pCLXSN system provided by Dr. I. Verma (30). The
cDNAs for GFP and Tax were cloned into the pCLXSN retroviral vector
by standard methods, and the procedure for retrovirus production and
infection was as previously described (21) except for the inclusion of
vesicular stomatitis virus glycoprotein (provided by Dr. T. Friedmann
(31)) in the packaging.
RT-PCR and RNase Protection Analyses--
Total RNA was isolated
from the various T-cell lines using TRI reagent (Molecular Research
Center, Cincinnati, OH). RT-PCR analysis was performed as
described (21) using the following primers: TRAIL, forward,
GGCTATGATGGAGGTCCAGG, and reverse, GGTCCATGTCTATCAAGTGCTC; GAPDH,
forward, CTCATGACCACAGTCCATGCCATC, and reverse, CTGCTTCACCACCTTCTTGATGTC.
The RNase protection assays were performed using the RiboQuant
Multi-probe RPA System (hAPO-3 template set, PharMingen) following the
manufacturer's instruction.
Apoptosis Assay--
Apoptosis was analyzed based on the
translocation of phosphatidylserine from the inner side of the plasma
membrane to the outer layer during the early stages of apoptosis (32).
Briefly, the indicated cells were stained with annexin V-FITC and
propidium iodide, and the apoptotic cells were subjected to two-color
FACS analysis (21). The early and late stage apoptotic cells are stained with annexin V and annexin V-propidium iodide,
respectively, whereas the live cells are not stained (double negative).
IKK Tax-induced Apoptosis Is Blocked by Anti-TRAIL- but Not
Anti-Fas-blocking Antibodies--
To further investigate the mechanism
of Tax-induced T-cell death, we examined the involvement of two
important apoptosis-inducing molecules, FasL and TRAIL. Specific
blocking antibodies for these two proteins were incubated with the
Tax-expressing cells followed by measuring the effect of this treatment
on Tax-mediated apoptosis. In agreement with a prior study (23), the
Fas antibody did not generate an appreciable protective effect on
Tax-induced cell death (Fig. 2,
column 4). In contrast, the TRAIL-blocking antibody efficiently inhibited this virus-specific event (column 5).
This finding suggests that TRAIL, but not FasL, is involved in
Tax-induced apoptosis in Jurkat T cells.
Tax Induces the Expression of TRAIL mRNA--
We then examined
whether Tax induces TRAIL gene expression. RT-PCR analysis revealed a
strong induction of TRAIL mRNA by PMA and ionomycin (lane
2), mitogens that mimic the T-cell activation signals (Fig.
3A, upper panel).
Interestingly, the TRAIL mRNA was also induced upon Tax expression.
Parallel immunoblotting analysis readily detected the Tax protein in
the infected cells (Fig. 3A, lower panel). This result,
which was confirmed by the more quantitative RNase protection assays
(see Fig. 4), is in complete agreement
with the finding that the TRAIL pathway is important for Tax-induced
apoptosis (Fig. 2). We also examined TRAIL mRNA expression in a
number of HTLV-transformed T cell lines (C8166, HUT102, LAF, MT2, and
SLB-1) as well as control uninfected T-cell lines (Jurkat, Molt4, and
SupT1) using RNase protection assays (Fig. 3B). Little or no
TRAIL mRNA was detected in the HTLV-negative cell lines
(lanes 1, 7, and 10). Consistent with the RT-PCR result,
stimulation of Jurkat cells with PMA and ionomycin led to strong
induction of TRAIL mRNA expression (Fig. 3B, middle panel, lane 2), which was further potentiated by
cross-linking the CD28 costimulatory molecule using an agonistic
antibody (anti-CD28) (lane 3). More importantly, TRAIL was
constitutively expressed in all of the HTLV-transformed T cell lines
except C8166 (Fig. 3B, middle panel, lanes
4, 5, 6, 8, and 9). Internal control assays revealed that the expression of caspase 8 was ubiquitous and not enhanced in HTLV-transformed cells (Fig. 3B, upper panel).
Further, the total RNA amount in the different samples was similar, as demonstrated by the close to equal expression of a house-keeping gene
(ribosomal L32). These results suggest that TRAIL gene expression is
induced by HTLV-I infection and maintained in most of the
virus-transformed cell clones.
Induction of TRAIL mRNA by Both Tax and T-cell Mitogens
Requires the NF-
In the same RNase protection assay, we also examined the expression of
caspase 8, FasL, and Fas, as well as TRAIL receptors, including the
decoy receptors DcR1 and DR3 and the killing receptors DR4 and DR5. As
previously demonstrated (21), the mitogen-mediated FasL mRNA
induction was not blocked by the IKK The NF- Although Tax is best known for its T-cell activation function, several
studies have demonstrated a potent apoptosis-inducing activity of this
viral oncoprotein (6, 23, 35). It has been consistently difficult to
generate stable T-cell lines expressing high levels of Tax. Indeed,
retrovirus-mediated expression of Tax in Jurkat T cells results in
massive cell death within a few days in culture (Fig. 1). The
Tax-induced Jurkat cell death can be blocked by a caspase inhibitor,
zVAD (data not shown and Ref. 23), suggesting the involvement of common
intracellular mediators of apoptosis. However, it has remained unclear
how Tax initiates the apoptosis pathway. Tax has been shown to
stimulate the promoter activity of FasL in reporter gene assays (35,
36) and enhance the level of FasL mRNA (23). However, Tax-induced
T-cell death is largely insensitive to FasL-specific blocking
antibodies (Fig. 2 and Ref. 23). This finding is somewhat surprising
because Jurkat cells express high levels of Fas and are sensitive to
Fas-mediated apoptosis (21). Our current study could explain these
previous findings. Using the sensitive and specific RNase protection
assays, we have shown that TRAIL, but not FasL, is strongly induced in Tax-expressing Jurkat cells (Fig. 4) as well as in various
HTLV-transformed T-cell lines (Fig. 2B and data not shown).
Indeed, a TRAIL-blocking antibody can effectively inhibit Tax-induced
apoptosis in Jurkat cells. Our studies suggest that TRAIL is a major
mediator of Tax-induced T-cell death.
B signaling. Tax fails to induce
apoptosis in T cells lacking I
B kinase
(IKK
), an
essential component of the NF-
B signaling pathway. This defect was
rescued when the mutant cells were reconstituted with exogenous IKK
.
We further demonstrate that the Tax-induced T-cell death is mediated by
TNF (tumor necrosis factor)-related apoptosis-inducing ligand (TRAIL), because this event can be effectively inhibited by a TRAIL-blocking antibody. Consistent with this functional aspect, Tax stimulates the
expression of TRAIL mRNA. Finally, we provide genetic evidence demonstrating that the NF-
B signaling pathway is essential for TRAIL
gene induction by both Tax and T-cell activation signals. These studies
reveal a novel function of the NF-
B signaling pathway and suggest a
key mechanism by which Tax induces T-cell death.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-subunit of the high affinity IL-2 receptor (10). Induction of many cellular genes by Tax is mediated through activation of NF-
B, a key regulator of genes involved in
cell activation and growth (11, 12). Recent biochemical and genetic
studies demonstrate that Tax activates NF-
B by stimulating the I
B
kinase (IKK) (13-18), a multisubunit protein complex specifically phosphorylating the NF-
B inhibitory protein, I
B
(19). The IKK
holoenzyme is composed of two catalytic subunits, IKK
and IKK
,
and a regulatory subunit, IKK
. Although lacking catalytic activity,
IKK
is essential for IKK activation by both cellular stimuli and Tax
(16, 17, 20). A Jurkat T-cell mutant lacking IKK
is defective in
NF-
B activation by T-cell mitogens and Tax (17). This genetically
manipulated T-cell system has been useful for a number of recent
studies (17, 21, 22).
, Fas ligand (FasL), TNF-related apoptosis-inducing ligand (TRAIL), and other related proteins, all of which induce cell
death by binding to their specific receptors on target cells (25). FasL
plays a critical role in activation-induced cell death, which
occurs in antigen-stimulated T cells (26). However, the FasL pathway is
not important for Tax-mediated apoptosis induction (23). Here, we
present genetic evidence suggesting that the Tax-induced T-cell death
is largely mediated by TRAIL. Tax expression in Jurkat T cells results
in potent induction of TRAIL gene expression, which is associated with
massive cell death. This Tax-induced cell death can be inhibited with a
TRAIL-blocking antibody. Interestingly, both the Tax-induced TRAIL gene
expression and cell death require an intact NF-
B signaling pathway.
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
, have been
described previously (17, 21). JM4.5.2 lacks expression of IKK
and
thus is defective in NF-
B activation by both cellular signals and
Tax. The JM4.5.2-GFP and JM4.5.2-IKK
are derivatives of JM4.5.2
stably reconstituted with green fluorescence protein (GFP) and IKK
,
respectively. The Molt-4 and SupT1 T-cell lines were provided by the
AIDS Research and Reference Program of NIAID, National Institutes of
Health. These cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine,
50 units/ml penicillin, and 50 µg of streptomycin. LAF is an
IL-2-dependent HTLV-immortalized human T-cell line (kindly
provided by Dr. G. Franchini (27)). C8166, HUT102, MT-2, and SLB-1 are
IL-2-independent HTLV-I transformed T-cell lines (14).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
Is Required for Tax-induced Apoptosis in Jurkat
Cells--
To investigate the mechanism mediating Tax-induced T-cell
death, we utilized a genetically manipulated T-cell system previously characterized in our laboratory (17, 21). This system includes an
IKK
-deficient mutant Jurkat T-cell line, JM4.5.2, the parental Jurkat cells, and JM4.5.2 cell derivatives reconstituted with GFP
(JM4.5.2-GFP) or IKK
(JM4.5.2-IKK
). The JM4.5.2 and JM4.5.2-GFP cells are defective in NF-
B activation by both mitogens and Tax, whereas the parental Jurkat and JM4.5.2-IKK
are competent in this
cellular signaling pathway (17, 21). For efficient Tax expression, we
infected the cells with a retroviral expression vector encoding Tax.
Under these conditions, more than 95% of the cells were infected as
assessed by a parallel infection using GFP-expressing retroviruses
(data not shown). Consistent with a prior study (6), expression of Tax
in the parental Jurkat T cells resulted in marked induction of cell
death, whereas the mock infected cells (infected with retroviral vector
lacking a cDNA) did not exhibit significant cell death beyond the
background level detected in uninfected cells (Fig.
1A). More importantly, the
Tax-induced cell death was markedly reduced in the IKK
-deficient cells (Fig. 1B, middle panel). This functional
blockade specifically resulted from the IKK
defect, since the
induction of cell death was restored when the JM4.5.2 cells were
reconstituted with IKK
(bottom panel). Such a pattern of
cell death was more clearly demonstrated in a time course study (Fig.
1C). Although the majority of the IKK
-competent cells
died within 10 days after Tax infection, no significant killing was
detected in the IKK
-deficient cells over the entire time course.
Further, the differential survival rates between the IKK
-positive
and IKK
-negative cells did not result from variation in Tax
expression (Fig. 1D). These results clearly demonstrate that
the NF-
B signaling pathway is essential for Tax-induced Jurkat cell
death.

View larger version (29K):
[in a new window]
Fig. 1.
The NF-
B signaling
pathway is required for Tax-induced apoptosis in Jurkat cells.
A, FACS profiles of apoptosis assays in Jurkat cells. Jurkat
cells were either not infected, mock infected with empty pCLXSN vector
(Vector), or infected with pCLXSN-Tax (Tax).
Three days post-infection, the cells were stained with annexin V-FITC
and propidium iodide and subjected to FACS analysis. The cells
singly stained with annexin V (lower right) and doubly
stained with PI-annexin V (upper right) are early and
late phase apoptotic cells, respectively. The double negative cells
(lower left) are the surviving cells, the percentage of
which in the total cell population is indicated below the
graph. B, apoptosis analysis in parental (wild type
(Wt)) and mutant Jurkat cells. The cells were either not
infected or infected with Tax followed by apoptosis assays as described
in A. C, kinetics of Tax-induced apoptosis. Tax
was delivered to the different cells via retroviral infection, and
apoptosis assays were carried out at the indicated times as described
in A. The level of cell death is presented as the percent of
viable cells (double negative cells). D, RT-PCR analysis to
monitor the expression of Tax (upper panel) and a control
house-keeping gene, GAPDH (lower panel). RNA was prepared
from cells at 4 days post-infection.

View larger version (13K):
[in a new window]
Fig. 2.
Inhibition of Tax-induced cell death by a
TRAIL-blocking antibody. Jurkat T cells were either not infected
(None), mock infected with pCLXSN vector
(Vector), or infected with Tax (Tax). Some of the
infected cells were incubated with the indicated blocking antibodies.
At 3 days post-infection, the cells were subjected to apoptosis assays
as described in Fig. 1. The percent of viable cells (double negative
cells) in the total cell population is presented.

View larger version (31K):
[in a new window]
Fig. 3.
TRAIL mRNA expression in Tax-expressing
and HTLV-transformed T cells. A, Jurkat cells were
either not treated (NT), stimulated for 8 h with PMA
plus ionomycin (P/I), or infected with Tax for 3 days and then collected for RNA preparation. RT-PCR was performed to
amplify both TRAIL and GAPDH mRNAs (upper panel). The
expression of Tax protein was monitored by immunoprecipitation with
anti-Tax followed by immunoblotting using the same antibody
(lower panel). B, RNase protection assay using
total RNA isolated from the indicated cells. C8166, HUT102, LAF, MT-2,
and SLB-1 are HTLV-infected T-cell lines. Jurkat, Molt-4, and SupT1 are
control uninfected T-cell lines. The Jurkat cells were either not
treated (NT) or stimulated with PMA plus ionomycin
(P/I) or P/I together with an agonistic anti-CD28
antibody (P/I/C). The protected RNA
fragments for caspase 8, TRAIL, and a house-keeping gene,
L32, are indicated.

View larger version (85K):
[in a new window]
Fig. 4.
Induction of TRAIL mRNA by both mitogens
and Tax is dependent on NF-
B signaling.
RNA samples were isolated from the indicated cells and subjected to
RNase protection assays. Analysis was performed 8 h after mitogen
(P/I) stimulation or 3 days after Tax infection.
The protected RNA fragments are indicated.
B Signaling Pathway--
If TRAIL is the mediator
of Tax-induced T-cell death, the expression of this death regulatory
gene may also require NF-
B signaling. To examine this possibility,
we performed RNase protection assays to detect the expression of TRAIL
mRNA in parental and IKK
-deficient Jurkat T cells (Fig. 4). As
expected, both mitogens and Tax stimulated TRAIL mRNA expression in
the wild-type Jurkat cells (lanes 1-3). Remarkably, the
TRAIL gene induction was almost completely blocked in the
IKK
-deficient JM4.5.2 cells (lanes 4-6). Further, this
functional defect was largely rescued when the mutant cells were
reconstituted with IKK
(lanes 10-12) but not with GFP
(lanes 7-9). Parallel immunoblotting assays readily detected Tax in all of the Tax-infected cell lines (data not shown). Together, these data clearly demonstrate that the NF-
B signaling pathway is essential for the inducible expression of the TRAIL gene.
deficiency (Fig. 4, lanes
5 and 8), which is in sharp contrast to the induction of TRAIL. Additionally, we found that Tax is not a strong inducer of
FasL, a result consistent with the dispensable role of the FasL/Fas
pathway in Tax-induced cell death (see Fig. 2). Further, Jurkat cells
exhibited constitutive expression of caspase 8, Fas, and DR5. Although
the levels of Fas and DR5 were enhanced in mitogen-stimulated parental
cells (lane 2), the inducible expression of these two genes
appeared to be only moderately affected by the IKK
deficiency.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
B signaling pathway plays an important role
in apoptosis regulation (33). Although strong evidence implicates
NF-
B as an antiapoptotic factor, there are studies suggesting that NF-
B may also function proapoptotically under certain situations (33, 34). The mechanism by which NF-
B promotes apoptosis remains
controversial. Although overexpression of the RelA subunit of
NF-
B induces FasL promoter activity, the NF-
B signaling pathway does not seem to be essential for the inducible expression of FasL in
Jurkat T cells (21). In the current study, we have demonstrated that
the NF-
B signaling plays a critical role in TRAIL gene induction by
both T-cell mitogens and the Tax protein. This finding suggests a novel
mechanism underlying the proapoptotic function of NF-
B.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Drs. G. Franchini, T. Friedmann, I. Verma, and H. Yagita, The Fred Hutchinson Cancer Research Center, the Immunex Corporation, and The AIDS Research and Reference Program of NIAID, National Institutes of Health, for reagents.
| |
FOOTNOTES |
|---|
* This study was supported by American Cancer Society Grant RPG-99-212-01-MBC and Public Health Service Grant 2 R01 CA68471 (to S.-C. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Microbiology
and Immunology, Pennsylvania State University College of Medicine, 500 University Dr., Hershey, PA 17033. Tel.: 717-531-4164; Fax:
717-531-6522; E-mail: sxs70@psu.edu.
Published, JBC Papers in Press, September 11, 2001, DOI 10.1074/jbc.C100501200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
HTLV-I, human T-cell
leukemia virus type I;
IL-2, interleukin-2;
IKK, I
B kinase;
FasL, Fas ligand;
TNF, tumor necrosis factor;
TRAIL, TNF-related
apoptosis-inducing ligand;
PMA, phorbol 12-myristate 13-acetate;
GFP, green fluorescence protein;
FITC, fluorescein isothiocyanate;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
RT-PCR, reverse
transcriptase-polymerase chain reaction;
FACS, fluorescence-activated
cell sorting.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Poiesz, B. F., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D., and Gallo, R. C. (1980) Proc. Natl. Acad. Sci. U. S. A. 77, 7415-7419 |
| 2. | Yoshida, M., Miyoshi, I., and Hinuma, Y. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 2031-2035 |
| 3. | Ressler, S., Connor, L. M., and Marriott, S. J. (1996) FEMS Microbiol. Lett. 140, 99-109 |
| 4. | Feuer, G., and Chen, I. S. Y. (1992) Biochim. Biophys. Acta 1114, 223-233 |
| 5. | Harhaj, E. W., Good, L., Xiao, G., and Sun, S.-C. (1999) Oncogene 18, 1341-1349 |
| 6. | Chlichlia, K., Moldenhauer, G., Daniel, P. T., Busslinger, M., Gazzolo, L., Schirrmacher, V., and Khazaie, K. (1995) Oncogene 10, 269-277 |
| 7. | Los, M., Khazaie, K., Schulze-Osthoff, K., Baeuerle, P. A., Schirrmacher, V., and Chlichlia, K. (1998) J. Immunol. 161, 3050-3055 |
| 8. | Grassmann, R., Berchtold, S., Radant, I., Alt, M., Fleckenstein, B., Sodroski, J. G., Haseltine, W. A., and Ramstedt, U. (1992) J. Virol. 66, 4570-4575 |
| 9. | Robek, M. D., and Ratner, L. (1999) J. Virol. 73, 4856-4865 |
| 10. | Smith, M. R., and Greene, W. C. (1991) J. Clin. Invest. 87, 761-766 |
| 11. | Grilli, M., Chiu, J. J.-S., and Lenardo, M. (1993) Int. Rev. Cytol. 143, 1-61 |
| 12. | Gilmore, T. D., Koedood, M., Piffat, K. A., and White, D. W. (1996) Oncogene 13, 1367-1378 |
| 13. | Yin, M.-J., Christerson, L. B., Yamamoto, Y., Kwak, Y.-T., Xu, S., Mercurio, F., Barbose, M., Cobb, M. H., and Gaynor, R. B. (1998) Cell 93, 875-884 |
| 14. | Uhlik, M., Good, L., Xiao, G., Harhaj, E. W., Zandi, E., Karin, M., and Sun, S.-C. (1998) J. Biol. Chem. 273, 21132-21136 |
| 15. | Geleziunas, R., Ferrell, S., Lin, X., Mu, Y., Cunningham, E. T., Jr., Grant, M., Connelly, M. A., Hambor, J. E., Marcu, K. B., and Greene, W. C. (1998) Mol. Cell. Biol. 18, 5157-5165 |
| 16. | Yamaoka, S., Courtois, G., Bessia, C., Whiteside, S. T., Weil, R., Agou, F., Kirk, H. E., Kay, R. J., and Israel, A. (1998) Cell 93, 1231-1240 |
| 17. | Harhaj, E. W., Good, L., Xiao, G.-T., Uhlik, M., Cvijic, M. E., Rivera, I., and Sun, S.-C. (2000) Oncogene 19, 1386-1391 |
| 18. | Sun, S.-C., and Ballard, D. W. (1999) Oncogene 18, 6948-6958 |
| 19. | Karin, M., and Ben-Neriah, Y. (2000) Annu. Rev. Immunol. 18, 621-663 |
| 20. | Rudolph, D., Yeh, W. C., Wakeham, A., Rudolph, B., Nallainathan, D., Potter, J., Elia, A. J., and Mak, T. W. (2000) Genes Dev. 14, 854-862 |
| 21. | Rivera-Walsh, I., Cvijic, M. E., Xiao, G., and Sun, S.-C. (2000) 275, 25222-25230 |
| 22. | Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K., and Tschopp, J. (2001) Mol. Cell. Biol. 21, 5299-5305 |
| 23. | Chlichlia, K., Busslinger, M., Peter, M. E., Walczak, H., Krammer, P. H., Schirrmacher, V., and Khazaie, K. (1997) Oncogene 14, 2265-2272 |
| 24. | Stennicke, H. R., and Salvesen, G. S. (2000) Biochim. Biophys. Acta 477, 299-306 |
| 25. | Orlinick, J. R., and Chao, M. V. (1998) Cell. Signal. 10, 543-551 |
| 26. | Russell, J. H. (1995) Curr. Opin. Immunol. 7, 382-388 |
| 27. | Cereseto, A., Diella, F., Mulloy, J. C., Cara, A., Michieli, P., Grassmann, R., Franchini, G., and Klotman, M. E. (1996) Blood 88, 1551-1560 |
| 28. | Kayagaki, N., Yamaguchi, N., Nakayama, M., Kawasaki, A., Akiba, H., Okumura, K., and Yagita, H. (1999) J. Immunol. 162, 2639-2647 |
| 29. | Alderson, M. R., Tough, T. W., Davis-Smith, T., Braddy, S., Falk, B., Schooley, K. A., Goodwin, R. G., Smith, C. A., Ramsdell, F., and Lynch, D. H. (1995) J. Exp. Med. 181, 71-77 |
| 30. | Naviaux, R. N., Costanzi, E., Haas, M., and Verma, I. M. (1996) J. Virol. 70, 5701-5705 |
| 31. | Sharma, S., Cantwell, M., Kipps, T. J., and Friedmann, T. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 11842-11847 |
| 32. | Vermes, I., Haanen, C., Steffens-Nakken, H., and Reutelingsperger, C. (1995) J. Immunol. Methods 184, 39-51 |
| 33. | Barkett, M., and Gilmore, T. D. (1999) Oncogene 69, 6910-6924 |
| 34. | Baldwin, A. S. (2001) J. Clin. Invest. 107, 241-246 |
| 35. | Chen, X., Zachar, V., Zdravkovic, M., Guo, M., Ebbesen, P., and Liu, X. (1997) J. Gen. Virol. 78, 3277-3285 |
| 36. | Rivera, I., Harhaj, E. W., and Sun, S.-C. (1998) J. Biol. Chem. 273, 22382-22387 |
This article has been cited by other articles:
![]() |
C. Fionda, F. Nappi, M. Piccoli, L. Frati, A. Santoni, and M. Cippitelli Inhibition of Trail Gene Expression by Cyclopentenonic Prostaglandin 15-Deoxy-{Delta}12,14-Prostaglandin J2 in T Lymphocytes Mol. Pharmacol., November 1, 2007; 72(5): 1246 - 1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Xu, J.-Y. Zhou, and G. S. Wu Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Is Required for Tumor Necrosis Factor {alpha}-Mediated Sensitization of Human Breast Cancer Cells to Chemotherapy. Cancer Res., October 15, 2006; 66(20): 10092 - 10099. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Grant, P. Jain, M. Nonnemacher, K. E. Flaig, B. Irish, J. Ahuja, A. Alexaki, T. Alefantis, and B. Wigdahl AP-1-directed human T cell leukemia virus type 1 viral gene expression during monocytic differentiation J. Leukoc. Biol., September 1, 2006; 80(3): 640 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zetterberg, W. A. Campbell, H. W. Yang, and W. Xia The Cytosolic Loop of the {gamma}-Secretase Component Presenilin Enhancer 2 Protects Zebrafish Embryos from Apoptosis J. Biol. Chem., April 28, 2006; 281(17): 11933 - 11939. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Okamoto, J.-i. Fujisawa, M. Reth, and S. Yonehara Human T-cell leukemia virus type-I oncoprotein Tax inhibits Fas-mediated apoptosis by inducing cellular FLIP through activation of NF-{kappa}B Genes Cells, February 1, 2006; 11(2): 177 - 191. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Reiley, M. Zhang, X. Wu, E. Granger, and S.-C. Sun Regulation of the Deubiquitinating Enzyme CYLD by I{kappa}B Kinase Gamma-Dependent Phosphorylation Mol. Cell. Biol., May 15, 2005; 25(10): 3886 - 3895. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. Thomas, G. M. Myhre, R. Tschumper, R. Sreekumar, D. Jelinek, D. J. McKean, J. J. Lipsky, W. J. Sandborn, and L. J. Egan Selective Inhibition of Inflammatory Gene Expression in Activated T Lymphocytes: A Mechanism of Immune Suppression by Thiopurines J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 537 - 545. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sieburg, A. Tripp, J.-W. Ma, and G. Feuer Human T-Cell Leukemia Virus Type 1 (HTLV-1) and HTLV-2 Tax Oncoproteins Modulate Cell Cycle Progression and Apoptosis J. Virol., October 1, 2004; 78(19): 10399 - 10409. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bohuslav, L.-f. Chen, H. Kwon, Y. Mu, and W. C. Greene p53 Induces NF-{kappa}B Activation by an I{kappa}B Kinase-independent Mechanism Involving Phosphorylation of p65 by Ribosomal S6 Kinase 1 J. Biol. Chem., June 18, 2004; 279(25): 26115 - 26125. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tripp, Y. Liu, M. Sieburg, J. Montalbano, S. Wrzesinski, and G. Feuer Human T-Cell Leukemia Virus Type 1 Tax Oncoprotein Suppression of Multilineage Hematopoiesis of CD34+ Cells In Vitro J. Virol., November 15, 2003; 77(22): 12152 - 12164. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Robbins, L. Maksumova, E. Pocock, and J. K. Chantler Nuclear Factor-{kappa}B Translocation Mediates Double-Stranded Ribonucleic Acid-Induced NIT-1 {beta}-Cell Apoptosis and Up-Regulates Caspase-12 and Tumor Necrosis Factor Receptor-Associated Ligand (TRAIL) Endocrinology, October 1, 2003; 144(10): 4616 - 4625. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Tabruyn, C. M. Sorlet, F. Rentier-Delrue, V. Bours, R. I. Weiner, J. A. Martial, and I. Struman The Antiangiogenic Factor 16K Human Prolactin Induces Caspase-Dependent Apoptosis by a Mechanism that Requires Activation of Nuclear Factor-{kappa}B Mol. Endocrinol., September 1, 2003; 17(9): 1815 - 1823. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chaudhry, W. J. Freebern, J. L. Smith, W. G. Butscher, C. M. Haggerty, and K. Gardner Cross-Regulation of T Cell Growth Factor Expression by p53 and the Tax Oncogene J. Immunol., December 15, 2002; 169(12): 6767 - 6778. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |